Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer

Entrada Therapeutics (TRDA) appointed Linea Aspesi as Chief People Officer to help scale its people and organization.

Rhea-AI Summary

Entrada Therapeutics (TRDA) appointed Linea Aspesi as Chief People Officer to help scale its people and organization.

Aspesi brings more than twenty years of experience at biopharmaceutical and technology companies, including work scaling organizations from discovery through commercial stages. She previously served as Chief People Officer at KalVista Pharmaceuticals and held executive-level human resources roles at Editas Medicine, Forma Therapeutics, Saniona, Sobi and Genzyme Biologics Manufacturing.

Key Terms

oligonucleotide, myotonic dystrophy type 1

2 terms

oligonucleotide technical

"The Company’s lead oligonucleotide programs are in development"

A short chain of DNA or RNA molecules used to target, detect, or change specific genetic messages inside cells; think of it as a tiny, programmable instruction or zip code that can find and bind one exact genetic sentence. Investors care because oligonucleotides are the active ingredient in a growing class of precision therapies and diagnostics, so their success, manufacturing cost, and regulatory approval can directly affect a company's value and future revenue.

myotonic dystrophy type 1 medical

"VX-670, for myotonic dystrophy type 1"

A genetic, progressive disorder that causes muscle stiffness, weakness and a range of problems in other body systems (such as breathing, heart rhythm, vision and cognition); symptoms can vary widely and often worsen over time. For investors, it matters because its chronic, multisystem nature shapes the size of the potential patient population, the complexity and cost of clinical trials, regulatory requirements, and long-term demand for any effective treatments — think of it as a condition that requires multiple pieces to be fixed, not just a single part.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

A seasoned global people leader and organizational strategist, Ms. Aspesi will help scale Entrada’s people and organization for its next phase of growth

BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Linea Aspesi as Chief People Officer.

“Linea has a proven track record of scaling organizations and developing high-performing teams from discovery through commercial stages,” said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. “We are in a catalyst-rich period with our neuromuscular programs, and Linea brings deep experience that will be invaluable as we continue to build an industry-leading culture that enables Entradans to do their best work and deliver on the potential of our pipeline. People are the foundation of any organization, and at Entrada, we know that a strong and engaged team is critical to our ability to develop a new class of genetic medicines and ultimately bring them to the patients who need them most.”

“Entrada is a company with a clear and steady commitment to patients and to one another,” said Ms. Aspesi. “I’m thrilled to join the team at such an important time in Entrada’s growth and look forward to building on its strong, mission-driven culture and fostering an environment where our colleagues can continue to do their best work as we grow and advance our pipeline for patients.”

Ms. Aspesi is an organizational leader with more than twenty years of experience driving culture transformation at biopharmaceutical and technology companies ranging from small-cap to Fortune 500. With a focus on scaling organizations from discovery through commercial stages, she has led companies through critical inflection points while executing culture strategies that put people first and drive employee engagement and retention. Prior to Entrada, Ms. Aspesi served as Chief People Officer at KalVista Pharmaceuticals (acquired by Chiesi Group) and held multiple executive-level human resources leadership roles at life science companies including Editas Medicine, Forma Therapeutics, Inc. (acquired by Novo Nordisk), Saniona, Inc., Sobi, Inc., and Genzyme Biologics Manufacturing (acquired by Sanofi). Ms. Aspesi holds a BA in Education from the University of Massachusetts, Amherst.

About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn.

Forward-Looking Statements
This press release contains express and implied forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Entrada’s strategy, future operations, prospects and plans, objectives of management, the validation and differentiation of Entrada’s approach and EEV platform and its ability to advance its programs and provide a potential treatment for patients, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Entrada may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including the risks and uncertainties identified in Entrada’s filings with the Securities and Exchange Commission (SEC), including the Company’s most recent Form 10-K and in subsequent filings Entrada may make with the SEC. In addition, the forward-looking statements included in this press release represent Entrada’s views as of the date of this press release. Entrada anticipates that subsequent events and developments will cause its views to change. However, while Entrada may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Entrada’s views as of any date subsequent to the date of this press release.

Media Contact
Megan Prock McGrath
CTD Comms, LLC
megan@ctdcomms.com

Investor Contact
Doug Snow
Head of Investor Relations
dsnow@entradatx.com

Patient Advocacy Contact
Sarah Friedhoff
Head of Patient Advocacy
patientadvocacy@entradatx.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e3ca0d9c-6117-4c74-9bc2-21f28c13c1ea